Press Releases
SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, presented the Phase 1 clinical data of its first-in-class PD-1/IL-2α bispecific antibody fusion protein (R&D code: IBI363) in advanced solid... (continue reading...)
SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1... (continue reading...)
SAN FRANCISCO, U.S. and SUZHOU, China , June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, presented Phase 1 clinical data of IBI343 (TOPOi anti-CLDN18.2 ADC) for the treatment of advanced pancreatic ductal... (continue reading...)
SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the phase II trial data of KROCUS Study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with cetuximab for first-line non-small cell lung cancer (NSCLC) treatment,at the 2024 American Society of Clinical Oncology (ASCO) annual meeting.
The preliminary result of the... (continue reading...)
MONTREAL, QC / ACCESSWIRE / May 31, 2024 / Quebec Precious Metals Corporation (TSXV:QPM)(FSE:YXEP)(OTCQB: CJCFF) ("QPM" or the "Corporation") is pleased to announce the closing of the first tranche of a non-brokered private placement offering (the "Placement"), for an amount of $185,000. The Placement consists of 3,700,000 units ("Hard Units") of the Corporation at a price of $0.05 per Hard Unit. Each Hard Unit issued is comprised of one common share and one... (continue reading...)
More Press Releases
View Older Stories-
LENNY KRAVITZ ROCKS OUT AT THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®
-
Sun Bum Makes SPF Waves in Miami with its Largest Ever Beach Hangout for Skin Cancer Awareness Month
-
National Skills Champions are Honoured at the Skills Canada National Competition 2024, in Québec
-
Sapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation
-
BIOHACKING CONFERENCE ANNOUNCES STEMREGENⓇ WILL RETURN AS TITLE SPONSOR FOR 2025
-
Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting
-
First Federal Savings Bank and ICBA Offer Tips to Help Simplify the Homebuying Process
-
Cantargia ASCO Presentation Highlights Positive Clinical Data on Nadunolimab Counteracting Neuropathy
-
Sun, Sand, and Smooth Skin: Grab Ulike Air 10 for a Summer Beach Adventure
-
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
-
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
-
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Upd
-
Thrive with GBA | The Bay to Bay Dialogue held to deepen mutual understanding between China and US
-
All-in-One Job Shop Software for Fabrication Shops by Steelhead Technologies
-
Sustainable Tourism Initiative: Responsible Travel Merchandise Store Announced
-
What Custom Stickers Are Best for Glass?
-
Robotbulls - The Future of Cryptocurrency Trading: Integrating AI and Blockchain Data
-
Taseko Announces that Operations at its Gibraltar Mine have been Suspended
-
Michael Bernstein Offers Dropshipping Consulting to Help Clients Build Successful, Long-Term Businesses
-
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
-
PHILADELPHIA KICKS OFF PRIDE MONTH BY SETTING THE FIRST-EVER GUINNESS WORLD RECORDS™ FOR THE "LARGEST ATTENDANCE AT DRAG QUEEN STORY TIME"
-
Union members and allies mark Injured Workers’ Day in locations across Ontario
-
FameEX CEO’s Message: Keep the Intention in the Crypto Bull Market for a Better Departure
-
Prospera Energy Inc. Announces 2023 Financial Results
-
Z Grills Announces Unprecedented "Buy 1, Get 10 Grills" Promotion, Unlocking a Lifetime of Easier Grilling!
-
WATCH by Aisles: A Revolutionary AI System for Public Safety
-
CIO Women Magazine Spotlights Claudia Patricia Eusse, CEO, The Eusse Group, as Influential Women Leaders in Real Estate
-
Mr. Business Magazine Spotlights Diana Muniz-Lebrun, Founding Partner and CEO at Olympus Marketing
-
ICECO Launches APL35 on Indiegogo - The World's Lightest Aluminum Dual-Zone Freezer
-
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical
-
Tag along with Jason in Zhengzhou: Experiencing Kung Fu at the Shaolin Temple
-
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
-
"Experience the Luxury of Japanese Tradition and Cuisine" Reservations for the New Inbound Experience Tour in Osaka's Tondabayashi Begin on June 1, 2024!
-
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-sma
-
Gregory P Lee Personal Injury Lawyer The Woodlands Expands Services to Meet Rising Demand in Texas for Personal Injury Cases
-
Innovative Solutions and Cutting-Edge Technologies Take Centre Stage at Water Expo Delhi 2024
-
Revolutionizing Sustainability: The Environment Protection Technologies Expo
-
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
-
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
-
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
-
Fungies Mushroom Gummies Announces Major Retail Expansion and Availability at Walmart
-
Vincent Todd Announces the Introduction of Todd Agriscience
-
Hyundai Motor America Reports May 2024 Sales
-
Beverly Hills MD Celebrates Its 10th Anniversary
-
American Cancer Society and American Society of Clinical Oncology Unite to Create One of the Largest and Most Comprehensive Online Sources of Credible Cancer Information
-
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
-
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
-
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
-
ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System